Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 May 2020: Trial registered, NCT04389632
  2. 8 Jun 2020: Trial started, NCT04389632

The trials

NCT04389632: A Study of Sigvotatug Vedotin in Advanced Solid Tumors

State
Under way
Phase
Phase 1
People
1,006 planned
Started
8 Jun 2020
Primary completion
16 Jun 2027
Arms
Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCC, Part D: sigvotatug vedotin combination therapy in 1L HNSCC
Results
None posted
  1. 15 May 2020: Trial registered
  2. 8 Jun 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.